| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/NDT/GFP384 |
| P698 | PubMed publication ID | 19666665 |
| P2093 | author name string | Piet M ter Wee | |
| Jaap van den Born | |||
| Robert H J Beelen | |||
| Margot N Schilte | |||
| Eelco D Keuning | |||
| Paolo Fabbrini | |||
| Mammad Zareie | |||
| P2860 | cites work | COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer | Q24651871 |
| The biology of VEGF and its receptors | Q27860704 | ||
| Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention | Q29620087 | ||
| The role of cyclooxygenases in inflammation, cancer, and development | Q33814331 | ||
| Many actions of cyclooxygenase-2 in cellular dynamics and in cancer | Q34539982 | ||
| Cyclooxygenase-2: a therapeutic target in angiogenesis. | Q35077006 | ||
| Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy | Q35575515 | ||
| Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. | Q36297654 | ||
| Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors | Q36498885 | ||
| Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane | Q37123283 | ||
| Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts | Q41910302 | ||
| Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase | Q42450205 | ||
| Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat peritoneum | Q44321432 | ||
| Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo | Q44647163 | ||
| The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. | Q46474619 | ||
| Simulations of osmotic ultrafiltration failure in CAPD using a serial three-pore membrane/fiber matrix model. | Q51929308 | ||
| Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. | Q52933446 | ||
| A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells. | Q53580242 | ||
| Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. | Q54575451 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ultrafiltration | Q559573 |
| sclerosing encapsulating peritonitis | Q26805194 | ||
| P304 | page(s) | 3669-3676 | |
| P577 | publication date | 2009-08-07 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis | |
| P478 | volume | 24 |
| Q36260973 | A Novel Mouse Model of Peritoneal Dialysis: Combination of Uraemia and Long-Term Exposure to PD Fluid |
| Q37892307 | Angiogenesis in peritoneal dialysis |
| Q61450664 | Biocompatible Peritoneal Dialysis: The Target Is Still Way Off |
| Q42855202 | Bioincompatible impact of different peritoneal dialysis fluid components and therapeutic interventions as tested in a rat peritoneal dialysis model |
| Q37110171 | Cyclooxygenase-2 Inhibitor Reduces Hepatic Stiffness in Pediatric Chronic Liver Disease Patients Following Kasai Portoenterostomy. |
| Q54358692 | Effect of peritoneal dialysis on expression of vascular endothelial growth factor, basic fibroblast growth factor and endostatin of the peritoneum in peritoneal dialysis patients. |
| Q28390104 | Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis |
| Q37969041 | Modulation of lymphangiogenesis: a new target for aspirin and other nonsteroidal anti-inflammatory agents? A systematic review |
| Q34295316 | Nanotechnology and adeno-associated virus-based decorin gene therapy ameliorates peritoneal fibrosis |
| Q36831478 | Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis |
| Q42492768 | New Insights into the Effects of Chronic Kidney Failure and Dialysate Exposure on the Peritoneum |
| Q38187841 | Pharmacologic targets and peritoneal membrane remodeling |
| Q38024974 | Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions |
| Q40277283 | Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis |
| Q58710420 | Roles of the TGF-β⁻VEGF-C Pathway in Fibrosis-Related Lymphangiogenesis |
| Q47974720 | Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis |
| Q26783022 | The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis |
| Q38602815 | The Role of Tyrosine Kinase Receptors in Peritoneal Fibrosis |
| Q48364814 | The monocyte chemoattractant protein-1 (MCP-1)/CCR2 system is involved in peritoneal dialysis-related epithelial-mesenchymal transition of peritoneal mesothelial cells. |
Search more.